In conclusion, the findings of the study indicate that ADRs related with antihypertensives among CKD patients were not associated with CYP3A5*3 polymorphism alone among our study cohort, which requires verification through further studies with greater sample size. This evidence concerns the gene CYP3A5 and chronic kidney disease.